Item 2.02. Results of Operations and Financial Condition.

Marinus Pharmaceuticals, Inc. (the "Company") issued a press release on November 9, 2020 announcing its financial results for the quarter ended September 30, 2020 and providing a business update. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02.

The information furnished pursuant to this Item 2.02 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company's filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. Except as required by law, we undertake no duty or obligation to publicly update or revise the information so furnished.

Item 9.01. Financial Statements and Exhibits.






(d) Exhibits




Exhibit
  No.       Description

  99.1        Press Release, dated November 9, 2020, of Marinus Pharmaceuticals,
            Inc.
104         The cover page from this Current Report on Form 8-K, formatted in
            Inline XBRL




                                       2

© Edgar Online, source Glimpses